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ABSTRACT 
The American University in Cairo 
In silico design of selective high affinity ligands against HCV using novel computational biology 
tools 
 
Reem Rafik Al Olabi 
 
Dr. Hassan Azzazy 
Dr. Rod Balhorn 
Dr. Adam Zemla 
 
 
Background: Hepatitis C virus (HCV) infects 170 million patients worldwide. The absence of an 
effective mean of treatment or prophylaxis makes HCV infection a serious public health problem. 
Generating selective high affinity ligands (SHALs) against HCV could provide a solution to this public 
health burden. HCV E2 glycoprotein is required for HCV entry into host cells. It binds to CD81, a  
host receptor protein that belongs to the tetraspanin family and plays a critical role in viral invasion. 
HCV protease is essential for the cleavage of non structural proteins, in addition to preventing the 
phosphorylation of human interferon regulatory factor 3 and thus prevents the anti-viral response.  
Objective: To design a cocktail of SHAL-based inhibitors against several target proteins such as 
CD81, HCV E2, and HCV protease and optimize the currently available E2 homology models. 
Methods and findings: Different homology modeling techniques such as AS2TS, Phyre, 
ROSETTA and TASSER, were used to obtain reliable models of HCV NS3 serine protease and 
HCV E2 glycoprotein. LGA was used to structurally analyze the models in addition of clustering 
the obtained models and finding the closest structural templates using StralCP. Auto Dock Tools 
1.5.6 was used to prepare the crystal structures of the CD81-LEL protein (1G8Q and 1IV5), HCV 
protease, HCV polymerase and the homology model of HCV E2 by deleting water molecules, adding 
polar hydrogens, and assigning Gasteiger charges and to create a grid bounding box, which 
provided the desired grid parameter file using 0.375 A spacing. Autoligand, an AutoDock tool, was 
used to identify several binding sites on the protein targets. Fill points were created using a 1 A grid, 
and the calculations were performed using 10 to 210 fill points. AutoDock 4.2 was used to screen 
30,000 ligands obtained from different libraries (NCI_DSII, Sigma and Asinex) and identify small 
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molecules that might bind to each site. The docking results were analyzed and the top 20 ligands for 
each binding site on the target proteins were ranked according to selection criteria required for the 
design of promising SHALs. Distances between pairs of bound ligands were estimated and used to 
design several SHALs that should bind selectively to the target proteins. 
Conclusion: New computational tools have been used to design in silico several SHAL-based 
inhibitors that might have the potential to prevent both HCV entry into hepatocytes and the 
production of inflammatory cytokines that accelerate liver damage when targeting E2-CD81 
interaction. It might alter protein processing and viral replication if HCV protease was targeted. By 
targeting HCV RNA dependent RNA polymerase, the HCV replication could be blocked. In addition, 
blocking the complexation of NS3 with the NS4A co-factor will render it non functional and thus 
block the replication process and disrupt the HCV life cycle. If a reliable E2 homology model 
was developed based on different studies and validations, it could help generate selective high 
affinity ligands that block the earliest phase of the HCV life cycle. 
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CHAPTER 1: LITERATURE REVIEW 
Hepatitis C virus is considered a global public health burden, infecting approximately 170 million 
patients worldwide [1]. HCV was discovered 15 years ago by Houghton et al. paving the way for the 
development of different drugs and diagnostics against HCV [2]. Determining the HCV structure, 
translated proteins, their functions and the replication machinery made it easier for research groups 
worldwide interested in this field to develop novel HCV antiviral drugs. Interferon has been used to treat 
chronic HCV infection since 1986, which means before non A non B (NANB) infection was known as 
HCV. The therapy was optimized by developing peginterferon (PEG-IFN) so as to improve the 
pharmacokinetics of IFN and increase the response to treatment [3, 4]. Although effective, the 
monotherapy interferon (IFN) or combination therapy (IFN/Ribavirin) led to many side effects making this 
treatment patient non-compliant. The side effects are caused by the non selectivity of IFN which affects 
both the normal cells and the infected hepatocytes. This made different research groups think of 
alternatives that target either the host proteins involved in HCV infection [5 , 6, 7, 8] or HCV proteins [9, 
10, 11]. Several approaches were tried in developing new therapeutics against HCV [12, 13, 14, 15, 16]. 
Recently, a novel approach was developed to generate selective high affinity ligands against a protein on 
lymphoma [17, 18, 19, 20]. This approach proved to be successful in developing highly selective and 
robust SHALs with high specificity towards the target, thus leading to the idea of applying such an 
approach to develop drugs against HCV targeting different levels of HCV life cycle such as the entry 
phase (E2-CD81-LEL interaction) and the polyprotein cleavage phase (HCV NS3-4A serine protease 
complex).  
Targeting HCV proteins to develop anti-HCV drugs 
HCV E2 glycoprotein 
Several approaches are being used to develop anti-HCV drugs and vaccines against HCV E2 
glycoprotein. Developing monoclonal and polyclonal antibodies is one of the approaches used. XTL 
Biopharmaceuticals reported that a combination of the monoclonal antibodies AB68 and AB65 (AB6865) 
was more effective than each one alone [21]. Both monoclonal antibodies were obtained by immortalizing 
peripheral blood mononuclear cells obtained from the blood of HCV infected patients. It was observed 
that AB6865 combination can identify different conformational epitopes on E2 and immune-precipitate 
different strains of HCV particles. The viral clearance takes place upon formation of immune complexes 
by endocytosis since that AB6865 induces phagocytosis of the immune complexes by neutrophils [21-24]. 
Bavituximab® is another monoclonal antibody developed by Peregrine pharmaceuticals, that acts against 
a unique target,  phosphatidyl serine. Phosphatidylserine is a lipid molecule normally found in the interior 
of cellular membranes and becomes exposed on the cell surface of cell membranes of viruses and host 
infected cells during replication. It has been reported that the presence of the phosphatidyl serine on the 
 7 
 
surface of the membranes of viruses creates a masking effect and thus helps the virus to evading the 
host immune response. This monoclonal antibody can be used against several viruses such as HIV, 
CMV, influenza and HCV.  When comparing Bavituximab with other monoclonal antibodies, it was found 
to be more advantageous because it has high specificity towards cells infected with viruses only. In 
addition it targets a molecule in the host and thus won‟t be affected by any viral mutations [25, 26]. 
Human hepatitis C immune globulin or Civacir is a polyclonal antibody obtained from human plasma 
enriched with HCV polyclonal antibodies collected from screened donors. It is used to prevent the re-
infection of HCV infected patients who had a liver transplant [27]. Another approach is to develop a 
vaccine that triggers passive immunity against HCV. It was found that immunoglobulin G obtained from 
HCV infected patients could be a good candidate for developing such a vaccine. Vanwolleghem et al. 
injected 8 chimeric mice with immunoglobulin G obtained from HCV infected patients, which were then 
challenged with 100% infectious dose of the acute phase HCV. Five out of eight mice developed 
immunity against HCV [27]. Law et al. [28] were able to isolate polyclonal antibodies that bind specifically 
to HCV E2 and neutralize several HCV strains. Full length immunoglobulins G were obtained from 3 
antibody-antigen binding fragments that bound to 3 antigenic regions on E2. Monoclonal antibodies were 
obtained from these immunoglobulins and were injected intraperitoneally in mice with high levels of 
human liver chimerism. These mice were then challenged by HCV infected human serum, but the 
monoclonals didn‟t show the desired [28]. A third approach involves carbohydrate binding agents (CBA) 
against HCV E2. Since HCV envelope glycoproteins are highly glycosylated, carbohydrate binding agents 
(CBA) such as cyanovirin-N might prove to be promising in blocking HCV entry into the cells [29]. Several 
host receptors were found to be involved in HCV entry by either mediating viral attachment (such as LDL-
R and Heparan Sulphate) [30] or by interacting with HCV E2 glycoprotein (such as CD81 and scavenger 
receptor BI (SR-BI)) [31-33]. Based on these findings new approaches were chosen such as developing 
small molecules that mimic the D-helix of CD81 and is known to interact with HCV E2 [12].  
E2 Homology Models 
There is no crystal structure available for HCV E2 glycoprotein, nor are there reliable homology 
models except for that developed by Yagnik et al. [34]. It is strongly believed that developing a reliable 
model of HCV E2 will be considered a break through because it will open another path for new category 
of anti-HCV drugs based on fragment based drug design and selective high affinity ligands approach.  
Yagnik et al. [34] applied several fold recognition methods (such as TOPITS and THREADER2) 
to develop an HCV E2 model using the envelope protein E of Tick Borne Encephalitis virus as a template. 
In addition they constructed two truncated E2 proteins by PCR. These two proteins (N2 and H strains) 
were used in heparin and CD81 binding studies. The aim of that study was to map the results obtained 
from experimental studies they performed onto their E2 model with the goal of identifying important 
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residues involved inE2:CD81 interaction and a heparin binding domain. The results obtained in this study 
were also used to propose a rough model for the quaternary structure of the envelope glycoproteins E1 
and E2 complex [34]. Figure 1 shows the developed E2 model of E2 with the significant residues 
involved in binding to CD81 and the E1:E2 heterodimeric association [34].  
The C-terminal ends of the E1 and E2 glycoproteins play important roles in E1-E2 
heterodimerization and retention in (ER). Charloteaux et al. [35] examined the C-terminal sequences of 
E1 and E2 in 25 HCV strains and used these sequences to generate several 3-D models. They found out 
that both domains of E1 and E2 should have a configuration of one amphipathic α helix followed by a pair 
of transmembrane strands. After generating 3-D models and minimizing the energy, the molecular 
hydrophobicity potentials (MHP) calculation and the IMPALA procedure (a Monte Carlo minimization of 
energy based simulation) were used to evaluate the C-terminal domains‟ interaction with the membranes. 
They concluded that the created 3-D models were consistent with the experimental studies in that both C-
terminal domains are involved in ER retention and in E1-E2 heterodimerization [35].  
Yu et al. [36] created a structural model of the HCV E2 protein using the Yagnik et al. sequence 
alignment. The template used was the crystal structure of the tick-borne encephalitis virus (TBEV) soluble 
E protein. The ectodomain of HCV E2 in this model was similar to that of domains I and II of TBEV E 
protein and HCV E1 glycoprotein was similar to domain II of TBEV E protein. They proposed that E1 and 
E2 glycoproteins form a tetramer that forms the basic building block of the outer shell of HCV where as in 
case of flavivirus (TBEV) the outer shell is formed of E-protein dimers (Figure 2) [36].  
Spiga et al. [37] reported a 3-D structure for the HCV E2 homodimer that was developed based 
on a secondary structure prediction using PsiPred. This was followed by fold recognition using  
GenThreader v.2.1. software. They used both the TBEV E-protein as a template and the alignment of the 
consensus sequence of six HCV E2 genotypes (1a, 1b, 2a, 2c, 3a, 4c) in building the E2 model using 
DeepView v.3.7 software. The model‟s sequence identity with the template was 14% and the structure 
exhibited little secondary structure (mainly B-sheets). In addition, molecular docking simulations were 
conducted to predict the HCV E2 dimeric assembly. The aim of this study was to find surface exposed 
protein sequences that could be immunoreactive in the HCV E2 glycoprotein (E2 mimotopes) and also 
common in most genotypes. Nine fragments were selected in the developed model (Figure 3), 
synthesized on nitrocellulose membranes and tested through binding assays using phosphate conjugated 
anti-HCV human antibodies. This approach was considered important because it might be used to 
develop diagnostic kits [37].  
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HCV NS3-4A serine protease 
The HCV NS3 protein, a bifunctional HCV enzyme, consists of 2 domains, an N-terminal serine 
type proteinase domain and a C-terminal NTPase/helicase domain [8, 4, 38]. NS4A is an important co-
factor required for the NS3 protease domain to function [4]. Targeting HCV enzymes such as HCV serine 
protease is considered a promising approach for developing new therapeutics for HCV. Several 
structures are present in the protein database for NS3 serine protease (ex. PDB ID: 3KN2) facilitating the 
development of drugs against it. Table 1 shows an example of HCV serine protease inhibitors under 
clinical trials [39-45].  
 
Host receptors involved in HCV entry  
SR-BI 
Scavenger receptor class 1B (SR-BI) is a polyprotein composed of 509 amino acids which 
belongs to CD36 family. Scarselli et al. have shown that human SR-BI is one of the putative receptors 
involved in HCV entry into the hepatocytes [7]. Bartosch et al. conducted a study to observe the effect of 
pre-incubation of the Huh-7 cell line with anti-SR-BI polyclonal antibodies. It was shown that these 
polyclonal antibodies reduced the infectivity of HCV pseudoparticles (HCVpp) [31].  Another study 
conducted recently by Lavillette et al. has led to the finding that SR-BI expression silencing reduced 
HCVpp infectivity as well [46].  HDL was found to be a natural SR-BI ligand that is internalized into the 
cell via non-clathrin dependent endocytosis. This led to the proposing SR-BI as one of the  receptors 
involved in triggering the internalization of  HCV into hepatocytes [7]. Catanese et al. generated a panel of 
MAbs against human SR-B1, and 2 of the antibodies (3D5 and C167) were found to block the soluble E2-
SR-BI interaction. They prevented the infection of Huh-7.5 with HCVcc in a dose dependent manner. 
Their study helped in proving that anti-SRBI MAbs might be promising HCV therapeutic agents [5].   
 
LDL-R 
Wunschmann et al. proposed LDL-R to be a putative receptor for HCV. They found that LDL-R 
might be involved in binding and entry of HCV into the host hepatocytes [47]. Mas Mraques et al.[48]  
conducted a study aiming at observing the effect of three single-nucleotide alterations within LDLR on the 
course of HCV infection and response to antiviral therapy. They concluded that these alterations affect 
the response to combination therapy and the self-limitation of HCV infection [48]. Owen et al.[49] 
proposed that anti-apolipoprotein E (apoE) antibody and beta-VLDL itself can block HCV entry by 
preventing HCV interaction with LDL-R thus blocking downstream interactions with other receptors. In 
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addition, siRNA and treatment with 25-hydroxycholesterol was found to decrease the HCV infection of 
cells [49].  
 
Tight junction proteins 
Two tight junction proteins, claudin-1 (CLDN-1) and occludin (OCLN) were found to be involved in 
HCV entry into the host cells [50]. Krieger et al. conducted a study to develop anti-CLDN-1 antibodies and 
observe their effects on HCV-host cell interaction. They found out that these antibodies blocked CLDN-1-
E2 interaction in addition to blocking the CLDN-1-CD81 association which is essential for internalization 
of HCV into the host. They concluded that targeting CLDN-1 might be promising in decreasing the 
infectivity of HCV by preventing the interaction of HCV E2 glycoprotein with the cell surface in addition to 
altering the CD81-CLDN-1 interaction [14].   
 
CD81-LEL 
Several research groups have found that the CD81- large extracellular loop (CD81-LEL) plays a 
key role in HCV entry into cells by binding to the HCV E2 glycoprotein [8, 51, 52]. Higginbottom et al. and 
Drummer et al. used mutational studies to identify residues that contribute to the E2-CD81-LEL 
interaction [52]. This information is important because it can be used to direct the design of a series of 
selective high affinity ligand-based inhibitors that block the E2-CD81-LEL interaction. [52,53]. Zhang et al. 
discovered a separate, additional function for CD81 in the HCV life cycle. These studies showed that 
CD81-LEL is important for efficient HCV genome replication [54]. In addition, E2-CD81-LEL interaction 
induces several immuno-modulatory effects, among which include in vitro a co-stimulatory signal in naive 
and antigen-experienced T cells that leads to the production of pro-inflammatory cytokine gamma 
interferon. Thus the CD81-E2-LEL interaction may play a role in T-cell-mediated liver inflammation and 
contribute to liver damage. In addition, the interaction of these two proteins down regulates T cell 
receptors and suppresses the activity of natural killer (NK) cells [53]. Meuleman et al. showed that using 
anti-CD81 as a prophylactic treatment completely protected human liver-uPA-SCID infection with different 
genotypes of HCV [55].  
 
A novel approach to develop anti-HCV drugs 
A novel approach was proposed by Balhorn et al. against lymphoma [17-20]. It was based on the 
generation of selective high affinity ligands (SHALs) which are small synthetic molecules that mimic the 
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targeting properties of monoclonal antibodies. They are created by  identifying two or three sets of 
molecules using computer docking methods, such as AutoDock, that are predicted to exhibit high binding 
affinity to the desired binding site in the target protein. One pair or more of these small molecules are 
linked together producing a series of bi- , tri- or bis-bidentate SHALs. When compared to monoclonal 
antibodies, they were found to be robust, easy to synthesize, and 1/50
th
 the size of MAbs making blood 
clearance faster and giving SHALs the ability to reach smaller blood vessels and hence targets more 
readily. The binding affinity of SHALs are expected to be significantly higher (by a factor of 100 to 
1,000,000) than that of each ligand alone. The SHALs developed by Balhorn et al. against HLA-DR10 
showed a binding affinity of nanomolar to picomolar Kd‟s to cell lines expressing HLADR10.  
In this project, this approach was implemented in the in silico design of SHALs against different 
targets involved in HCV infection. SHALs against CD81-LEL were designed using the data provided 
regarding the significant residues in CD81-LEL that are considered contact residues for HCV E2. Another 
set of SHALs were designed against HCV NS3 serine protease targeting the residues involved in the 
complexation of NS3 with its co-factor NS4A that is important for the function of NS3 serine protease. Our 
structural model of E2 was created using standard homology modeling methods. Based on an alignment 
provided by Yagnik et al. [34], the AS2TS system was used to create the initial model of E2. The detailed 
modeling of insertion, deletion and some loop regions was performed using the fragment-based method 
implemented in LGA_modeler program. Side chains were added by using SCWRL system. Then, in order 
to remove some steric clashes, and to refine structural model several iterations of MD simulation were 
performed. This last step in our modeling effort was assisted by using the Procheck system to verify the 
stereochemical quality of created final E2 model.  
Summary and conclusion 
HCV is a challenging virus due to its genomic diversity and not having the full picture of its 
mechanism of entry into the host cells. Several research groups identified important residues in HCV E2, 
CD81-LEL and HCV serine protease that are important in the completion of HCV life cycle. Using these 
information different approaches were used to develop drugs for treating HCV infection, either targeting 
HCV proteins or host receptors. Each of these targets has its advantages and disadvantages. Targeting 
HCV is better when the drugs target receptors in the liver specifically and prevent adverse events in other 
organs that might affect the normal homeostasis of the body is not a desired outcome, but targeting the 
host receptors is better when dealing with the continuous mutation of HCV and how it could develop 
resistance to drugs targeting it. For the picture to be complete, the mechanism of HCV entry must be 
completely unraveled clarifying the exact role of each of the already identified receptors involved in the 
entry and the ones that are not yet identified. SHALs approach was used in this project to target HCV 
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infection by designing SHALs against HCV and host proteins, such as HCV NS3 serine protease and 
CD81-LEL respectively. The anti-NS3 SHAL aims at altering its complexation with NS4A which is an 
important co-factor for the functioning of NS3 protease. The anti-CD81-LEL SHAL aims at blocking the 
E2-CD81-LEL interaction and thus preventing HCV entry, replication and propagation in addition to 
restoring the innate immunity of the host.   
 
  
 13 
 
CHAPTER 2: INTRODUCTION 
Hepatitis C virus 
History 
In early 1970s researchers discovered that there were more than the two known serotypes of 
hepatitis, hepatitis A and B. A third type was discovered and it was called non A non B (NANB) hepatitis. 
This discovery was a result of extensive work, which began by monitoring the participants in the study 
analyzing an abnormal pattern of aminotransferases bi-monthly for 6 to 12 months. This was followed by 
transfusion studies that were an eye opener on acute hepatitis. It was believed that the transfusion 
associated hepatitis would be hepatitis B but it wasn‟t. This was proven when the samples were found to 
be non reactive to hepatitis B tests. The stored sera from the transfusion studies were then used to 
inoculate chimpanzees, which later on developed biochemical abnormalities (e.g. Aminotransferases) 
indicating that NANB type was a transmissible agent. After 15 years of research, hepatitis C was 
identified by Houghton et al. [2]. Specific serological tests were developed and a comparison between 
NANB and hepatitis C confirmed that they are the same [56].  
HCV genomic diversity  
There are six major genotypes of HCV worldwide with RNA sequences that differ by >30 %. 
These genotypes are further classified into subtypes, isolates and quasispecies [57]. The continuous 
mutation of HCV is due to lack of efficient proof reading by the RNA dependent RNA polymerase in 
addition to the lack of the 5‟ to 3‟ exonuclease activity which leads to accumulation of mutations and viral 
escape [58]. The host immune‟s response is one of the major factors that affect the persistence of HCV 
infection leading either to viral clearance or to chronic infection. It is believed that there are positive and 
negative selection processes in which the beneficial mutations are selected and favoured over deleterious 
ones [59]. The HCV genotype is one of the most important predictive viral factors for the response to 
therapy. Other factors affecting response to therapy include sex and age of the patient, the initial viral 
load and the presence or absence of liver fibrosis [58]. 
Diagnosis 
Biochemical markers such as alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) may be elevated in the blood of patients with HCV and thus indicate the need for further testing. 
However, 40% of infected patients can have normal levels of ALT and AST making these enzymes of low 
significance in the diagnosis of HCV [60]. Fibro Test-Acti Test, is a non-invasive blood test and an 
alternate to liver biopsy for determining the level of fibrosis and necroinflammation that may be caused by 
HCV [61]. 
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Immunoassays are widely used for diagnosis of HCV infection. Four generations of enzyme 
immunoassays that detect antibodies against epitopes of different HCV proteins have been developed 
and used for serodiagnosis of HCV [61]. The core antigen has been proposed as a plasma marker for use 
in confirming an active infection [62]. Trak-C is an immunoassay that can detect free and antibody-bound 
core antigens and is used for screening blood donors and monitoring HCV treatment [62, 63].  
Molecular assays are crucial for the management of patients infected with HCV. Qualitative RNA 
tests are mainly used to confirm the presence of active HCV infection and for screening of blood donors. 
Quantitative tests are used for monitoring the response to therapy and prognosis.  Genotyping tests guide 
therapeutic strategies and aid the prediction of patient response to therapy [62].  
Current treatment 
HCV is currently treated using peginterferon (PEG-IFN) and ribavirin (RBV) [64]. Great efforts are 
being carried out to produce new drugs with higher efficacy, and better patient compliance by reducing 
their side effects, frequency of administration and easier routes of administration. Among the classes that 
are being developed are NS3 protease inhibitors, NS5B polymerase inhibitors, ribavirin analogs and 
cyclophilin inhibitors [65]. 
Epidemiology  
Hepatitis C virus infects approximately 3% of the world population. In the developed countries, 
the chronic HCV infection accounts for 70% of the patients, and acute HCV for 20%. 40% of the infected 
patients‟ progresses to end stage cirrhosis, 60% to hepatocellular carcinoma and 30% require liver 
transplantation [66]. Chronic hepatitis C prevalence ranges from 0.1% to 14.5% in different countries [67, 
1001,1002] and Egypt has the highest HCV prevalence worldwide (14.5%) [1002]. According to the WHO, 
about 20% of Egyptian blood donors are anti-HCV positive [1001].  
HCV genome and proteins 
HCV is a positive strand-RNA virus possessing a genome of approximately 9.5 kilobases which 
encodes a large polyprotein containing 3010 aminoacids [4]. The processing and cleavage of the 
polyprotein is performed using the machinery of the host and enzymes produced by the virus. Ten 
structural and non-structural proteins are produced upon cleavage of the polyprotein. Either pathway 
involves peptidase cleavage signals (Figure 4) [4]. There are two untranslated regions (UTRs) one at the 
5‟ end and one at the 3‟ end of the RNA [4, 68]. The structural proteins are the envelope glycoproteins 
denoted E1 and E2 and the core protein.  There are two other proteins of unknown significance known as 
“p7” and “F” proteins [4, 69]. As for the non-structural proteins; they are denoted NS2, NS3, NS4A, NS4B, 
NS5A, and NS5B [4, 69]. The structural proteins are released by the host machinery in the endoplasmic 
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reticulum, whereas the non structural proteins are released following cleavage by NS2-3 and NS3/4A 
protease. The C terminus of the capsid protein undergoes further processing triggered by a signal peptide 
peptidase [68]. Table 2 provides a brief description of the HCV proteins and their functions. Since the 
main HCV targets in this phase are HCV Envelope glycoproteins, and HCV NS3/4A complex, the next 
few paragraphs will provide more details on their nature and function [68].  
a) Envelope glycoproteins   
E1 and E2 glycoproteins are type I transmembrane proteins that possess a C-terminal 
transmembrane domain and an N-terminal ectodomain that is N-linked to glycans. The glycans were 
found to play a role in virus entry and glycoprotein folding [4]. Since HCV envelope glycoproteins are 
highly glycosylated, carbohydrate binding agents (CBA) such as cyanovirin-N might prove to be 
promising in blocking HCV entry into the cells [29]. Both proteins are cleaved from the polyprotein by 
host signal peptidase cleavage [3]. E1 and E2 form a natural non-covalent heterodimer that is 
retained in the endoplasmic reticulum (ER) [3, 4]. Their retention in ER contributes to HCV infection 
conversion into the chronic form because it cannot be detected by the host immune system and also 
proves that the virus is released from the host cells by budding and exocytosis [4]. Several host 
receptors were found to be involved in HCV entry by either mediating viral attachment such as LDL-R 
and Heparan Sulphate [30] or by interacting with HCV E2 glycoprotein such as CD81 and scavenger 
receptor BI (SR-BI) [31-33]. These interactions trigger HCV movement to the tight junctions and its 
uptake by Claudin-1 and its uptake via Claudin-1 and occludin [30]. Two hypervariable regions (HVR) 
have been identified in the HCV E2 glycoprotein sequence. HVR-1 is formed from the first 27 amino 
acids of the E2 N-terminus (ectodomain), and it largely contributes to the escape of the virus from the 
host immune response through what is called the viral-host evasion strategy by generating 
“quasispecies”. HVR-1 has also been shown to modulate HCV entry.  As for HVR-2, it has been 
described as an HCV entry modulator [3, 4]. Viral glycoproteins such as HCV E2 are considered to be 
a promising target to generate drug against because it plays an important role in host cell interaction 
and thus if blocked will dissect the HCV life cycle in its earliest phase. To achieve the objective of 
generating SHALs against E2, several HCV E2 homology models were constructed based on the 
previously developed homology model by Yagnik at al. [34] and using different structure prediction 
systems [69-71]. 
b) NS3/4A protein  
The HCV NS3 protein, which is bifunctional, consists of 2 domains, an N-terminal serine type 
proteinase domain and a C-terminal NTPase/helicase domain [3, 4, 15, 72]. NS4A is an important co-
factor required for the NS3 protease domain to function. NS4A participates in the folding of the N-
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terminal protease domain of NS3 by contributing one of its beta strands to the final structure. NS4A 
also leads to the change in the NS3 protease domain conformation, repositioning the catalytic triad. 
When NS3 is not associated with NS4A it is found to diffuse throughout the cytoplasm and nucleus, 
and this is attributed to not having a transmembrane domain. On the other hand NS4A is a 
membrane protein, thus by non-covalent association between NS3 serine protease and NS4A central 
domain, it will be associated with ER and ER-like membranes. In addition, NS4A stabilizes the NS3 
protease domain against proteolytic cleavage [4]. The NS3-4A protease complex is essential for 
cleaving the remaining HCV NS proteins (NS4B, NS5A and NS5B “RNA dependent RNA 
polymerase”) from the polyprotein. When HCV NS3-4A protease is inhibited, downstream NS proteins 
cleavage is halted preventing replication, and thus blocking further propagation of HCV [73]. Many 
companies and research groups have developed HCV protease inhibitors using structure-based drug 
design [74]. These inhibitors could not be developed until the HCV protease crystal structure became 
available in 1996 [75]. The NS3/4A complex is considered a significant target for development of anti-
HCV drugs [15].  
CD81 host receptor 
Several research groups have found that the CD81- large extracellular loop (CD81-LEL) is 
the domain involved in HCV entry via interaction with HCV E2 glycoprotein [76, 38-40]. Higginbottom 
et al. identified 4 amino acid residues that are of large significance in the E2-CD81 interaction using 
mutational studies. They found that the D196E mutation reduced the binding to E2. In addition 
mutations F186L and E188K inhibited binding of CD81 to E2 where as T163A enhanced their fusion 
[8] (Figure 6A). Drummer et al. identified an E2 binding site in CD81-LEL to occupy around 806 A°
2
. 
The most important contact residues they found within this site were Ile182, Phe186, Asn184, and 
Leu162 [53] (Figure 6B) [77-81]. The identification of these residues provides new targets for the 
design of selective high affinity ligands that could inhibit E2-CD81 interaction. Zhang et al. also 
discovered a novel function for CD81 in HCV life cycle. They found that CD81 is important for efficient 
HCV genome replication [15].  
This same group also discovered that the E2-CD81 interaction had several immuno-
modulatory implications, among which include inducing in vitro a co-stimulatory signal in naive and 
antigen-experienced T cells leading to production of pro-inflammatory cytokine gamma interferon. 
Thus the CD81-E2 interaction might play a role in T-cell-mediated liver inflammation and lead to liver 
damage. In addition, the interaction of these two proteins down regulates T cell receptors and 
suppresses the activity of natural killer (NK) cells [53]. Brazzoli et al. found out that CD81 is a central 
regulator for several events within the HCV life cycle. CD81 was found to activate Rac, Rho, and 
Cdc42 (Rho GTPase family) mediating the contact between HCV E2/CD81 complex with CLDN-1 and 
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occludin tight junction proteins to internalize HCV into the cell. Thus inhibiting CD81-HCV E2 
interaction will block these events as stated and will massively reduce the infectivity of HCV [82].  
Proposed model of HCV entry into hepatocytes 
HCV entry into the host cells involves several host receptors such as CD81 [33, 83, 84], the 
tight junction protein Claudin-1 (CLDN-1) [6, 14, 33, 83], scavenger receptor class BI [8, 33, 84]. LDL-
R [33, 83], mannose binding lectins DC-SIGN and L-SIGN [33], heparan sulphate proteoglycans [30, 
33] and the asialoglycoprotein receptor [33].  
Moradpour et al. [85] proposed that HCV particles become associated with low density 
lipoproteins (LDL) and very low density lipoproteins (VLDL). Thus it was concluded that LDL 
receptors are involved in the entry. Both glycosaminoglycans (GAGs) and LDL-R function as primary 
receptors that mediate the attachment of HCV to CD81 and SR-BI [30, 85]. CD81 and SR-BI trigger 
HCV movement towards the tight junction protein; CLDN-1 which act as co-receptor [ 85]. CLDN-1 
act at a late stage of entry which is followed by the internalization of HCV through Clathrin mediated 
endocytosis. It is suggested that HCV then moves inside the host cell in a low pH endosome where 
the acidification of the endosome helps mediate an HCV glycoprotein: endosomal membrane fusion 
(Figure 5A) [85]. It was found that the envelope proteins of other flaviviruses and alphaviruses (such 
as Semliki Forest virus and Dengue virus) possess an internal fusion peptide (class II fusion protein) 
that rearranges and trimerizes when exposed to low pH. This led to an assumption that HCV could 
involve class II fusion proteins in its internalization process [85, 86]. Budkowska [30] proposed a 
recent model of HCV entry based on the interaction of HCV: VLDL complex with LDL-R and/or 
heparan sulphate proteoglycan.  It was also proposed that HCV might interact directly with GAGs 
and/or SR-BI. SR-BI then approaches and forms a complex with CD81 which acts as a post entry 
receptor for HCV triggering signaling cascades that will help internalize HCV into the host cell. This is 
followed by the movement of HCV particles to CLDN-1 and OCLDN. OCLDN is considered as “the 
final entry key” in the HCV internalization process (Figure 5B) [30].  
 
Selective high affinity ligands  
Selective high affinity ligands (SHALs) are small synthetic molecules that mimic the targeting 
properties of monoclonal antibodies mainly in their targeting properties [87]. They are created by  
identifying two or three sites and corresponding sets of molecules using computer docking methods 
such as AutoDock that are predicted to exhibit high binding affinity to the desired binding site in the 
target protein. The components of SHALs are the best 2, 3 or 4 ligands of choice, and the linkers. 
There are specific criteria of selection that the top ligands must satisfy (Table 3). They are as follows: 
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General criteria: 
a. The ligands must have a free amino or carboxyl group 
b. If the ligand has both one carboxyl and one amino group it would be better than just one 
carboxyl or amino because if both groups are present the charged group will increase the 
ligand‟s solubility after modification and attachment to the linker. 
c. The ligands can‟t have 2 or more amino or carboxyl groups because of the difficulty of 
controlling which group will attached to the linker. 
Specific criteria: 
a. The free carboxyl or amino group of the ligand must be pointing away from the surface and is 
not predicted to interact with the protein 
b. The free amine or carboxyl must point toward the second site. 
c. Highly hydrophobic molecules are not favourable because they will reduce the solubility of 
the final product and might bind in more than one region. 
d. Compounds that are known to be highly toxic must be avoided. 
e. There must be a commercial source from which the ligand can be purchased because 
synthesizing the ligands may be difficult. 
f. Detergents must be avoided because they tend to bind to many proteins. 
g. Try to avoid compounds that might bind to more than one site on a protein (e.g. 
deoxycholate) must be avoided. 
h. Compounds that are known substrates, inhibitors or activators of other proteins/enzymes 
mustn‟t be selected, because the ultimate goal is to design selective SHALs against the 
desired target and thus decrease the side effects, but many small molecules that are 
commercially available happen to be non specific.  
i. Avoid peptides (natural sequences; FMOC, carbobenzoxy or other modified amino acids 
could be used because their side chains are modified so as that proteases can‟t detect it) 
because they can be cleaved by proteases and they will be unstable. 
j. Molecules that seem to interact with the surface (e.g. charges on surface and uncharged 
regions) in such a way that they are oriented in a particular direction should be selected. If 
they could flip and still bind due to symmetry or extend up into the solvent, they are not 
suitable. Because we need good points of interaction that we must be sure that fit inside the 
binding site, not on the surface of the protein exposed to solvent. But they should not be 
excluded specially for the third site. 
k. Compounds that might exist in different forms (e.g. enol vs ketol, etc) must be avoided. 
Because here it means that half of the population will be in the wrong tautomers. 
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l. Compounds that appear to interact through several points to the cavity could be selected 
because they will increase the binding affinity to the protein. The more context the higher the 
affinity. 
m. Compounds with functional groups that are highly reactive to the protein (to amines, 
carboxyls, etc) should not be chosen unless their reactivity can be used to create a 
permanent bond once the ligand binds.  
n. Ligands that are known to bind tightly to blood proteins (e.g. iodine containing compounds) 
must be avoided. The body has a system to recover iodide very efficiently and thus blood 
proteins tend to interact with iodinated compounds, where they become sequestered for long 
time which is totally unfavourable and non specific.  
o. Compounds that have disulfides in them (-S-S-) should not be used because they will be split 
by reducing agents. 
The linker design is determined  based on several factors: 
a) The distance between the ligands of choice 
b) The location of the free amino or carboxyl group present in the ligand 
c) If the 2 groups in the two ligands are different (one amino and one carboxyl) or the same ( 2 
amino or 2 carboxyl) 
d) The end result which is the desired dosage form and method of administration being oral or 
intravenous (IV).  
The components of the linker could be a combination of any of the following according to the above 
factors (Figure 7): 
 Polyethylene glycol (PEG): 
PEG has several advantages when being used as a linker component. A PEG unit short 
is (≈ 10 Å) and two or more PEG units can be linked together to increase the linker‟s length. PEG 
is inexpensive, and several clinical studies have shown that it is safe and causes no significant 
side effects [88]. Also the 2 oxygen atoms present in the PEG moiety, increase the solubility of 
the SHAL and may contribute to the SHALs binding affinity by being able to form H-bonds with 
the protein. PEG is used mainly to give length to the linker. 
 Lysine 
Lysine is used as a branching point making SHALs mimic the structure of an antibody. Lysine 
could be replaced with glutamic acid in the following cases: 
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a. If the distance between the 2 ligands was shorter than the length of a lysine 
b. If both free groups in the 2 ligands were amino groups since glutamic acid has 2 carboxyl 
groups. 
 Carbohydrate (CHO) linker to increase drug bioavailability when administered orally [89]:  
Points to consider: 
a. It is absorbed better in the gastrointestinal tract 
b. It is more soluble due to having more hydroxyl groups 
c. Its disadvantage is that since there are many hydroxyl groups, it is hard to control and 
block them and this can complicate the synthesis. Another disadvantage is the instability 
of some of the rings that may open up during the synthesis of SHALs.  
Protein structure modeling methods 
SHALs can be developed using either computational approach entirely in order to speed up the 
process or a completely experimental approach (i.e. High throughput screening methods) to identify the 
target. In the computational approach a reliable 3D structure of the target protein is used. There are 
several computational protein modeling techniques that can be used to obtain a good model of a protein 
that doesn‟t have a crystal structure by X-ray, NMR or others. These programs are helpful when there are 
sets of data available regarding the target protein and other homologous proteins from other organisms to 
serve as templates.  We applied some of these techniques to obtain reliable models of HCV NS3 serine 
protease for different HCV genotypes and compares them to crystal structures present. In addition, 
although HCV E2 is one of the most challenging proteins to be modeled, several models were created 
using different protein structure prediction techniques (Table 4).  
Amino acid Sequence to Tertiary Structure (AS2TS) system is one of the tools used in protein 
structure modeling [90]. It translates the amino acid sequences into standard protein databank (PDB) 
atomic coordinates. This system uses the closely related proteins from PDB to produce a set of 3D 
models for the desired target protein like HCV E2 or HCV NS3 serine protease in our case.  
Protein Structure and Function prediction Resource (PSiFR) is another system used in predicting 
the structure and function of proteins. Some proteins are of unknown functions, and thus special tools are 
needed to predict their function. The protein functional annotation depended mainly on the comparison of 
different protein sequences with known and unknown functions so as to try to find proteins with nearly 
similar functions. The need for new computational functional annotation tools based on structure and not 
sequence became needed recently due to the appearance of new proteins with sequences that had no 
similarity with other proteins, in addition, the protein tertiary structure is more conserved than the protein 
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sequence. PSiFR is a system based on TASSER threading technique for protein structure and function 
prediction [70, 71].  
ROSETTA is one of the software packages that is also used for protein structure and function 
prediction. It is used to predict protein structures in the presence or absence of experimental data of the 
target protein. In addition, it is used for protein-protein and protein-fragment docking experiments together 
with designing new proteins and redesigning previously existing ones. ROSETTA works by identifying the 
relevant conformation space when predicting the structure of a protein, and sequence space in case of 
protein design. This is followed by evaluating the energy of the obtained structural models [91].  
Protein Homology/analogY Recognition Engine (Phyre) is a fold recognition-based protein 
structure prediction system [72]. Structural Classification of Proteins (SCOP) database is the source of 
known protein structures used by Phyre server. These known structures are updated using newer 
depositions in the Protein Data Bank (PDB). Each of these structures‟ sequence is scanned against a 
non-redundant sequence database obtaining a profile which is then saved in the „fold library‟, where both 
the predicted structure and experimental structure of this protein are stored [72].  
Besides modeling, it is important to compare the different protein structures, models and 
fragments so as to obtain a reliable protein classification. Local-global alignment (LGA) is a method used 
to compare different protein structures and fragments. An LGA scoring function could help classify groups 
of proteins in addition to ranking the level of similarity between two structures [92]. 
STRucture ALignment-based Clustering of Proteins (STRALCP), is an algorithm that is used to 
determine regions in a given set of proteins that possess structural similarities. Those regions are then 
used for clustering, yielding protein classification schemes based on these structural similarities. 
STRALCP algorithm has several advantages such as its ability to cluster the same SCOP family 
separately by detecting the structural differences between their domains. Another advantage is being able 
to group proteins in different clusters based on the difference in length or if multi-domain proteins are 
found in different conformations [93] such as CD81-LEL which was found to be present in 2 different 
conformations [94]. 
Critical assessment of methods of protein structure prediction (CASP) is an experiment 
performed every year by the protein structure prediction groups throughout the world to assess different 
protein structure prediction methods. To date eight CASP workshops were conducted to determine the 
capabilities and limitations of current tools used in modeling protein structure from sequence. In addition, 
they are used to track the different improvements done in these tools. Assessments of methods are 
based on analyzing large number of blind predictions of protein structure [95]. 
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Most drugs developed or are being developed to disrupt ligand-receptor or protein-protein 
interactions. Thus, the presence of the experimental structure or molecular model is critical for the 
development of these kinds of drugs. If a structure is not available, computational molecular docking 
techniques are applied to protein models so as to predict potential bin ding sites, determine the different 
modes of interaction between the ligand and the target protein, and determine the binding affinity and 
energy of different ligands. 
AutoDock  
AutoDock is a group of tools that have been used for many years to perform virtual screens of 
small molecules binding to proteins molecular modeling [1003], and predict ligand-receptor interactions. It 
consists of two main programs. AutoDock is used to dock the ligand to the region of choice pre-defined by 
grid maps. AutoGrid, the second program, pre-calculates these grids [1003]. AutoDock Tools (ADT) is the 
graphical user interface [95, 96, 1003] that helps visualize the grid box and determine the desired site, in 
addition to analyzing the dockings [1003]. The scoring function of AutoDock uses a subset of the AMBER 
force field, implementing the united-atom model [95, 96]. AutoDock has many applications such as 
fragment based drug design, lead optimization, virtual screening, protein-protein docking, and 
combinatorial library design [1003]. In this study AutoDock was used to prepare the CD81-LEL receptor, 
calculate the grid map files and perform virtual ligand screening using the National Biomedical 
Computation Resources (NBCR) cluster [1004]. AutoLigand, a recently developed AutoDock tool, is used 
to predict potential binding sites in known protein structures. It works by finding the best fill points which 
have the largest possible interaction energy with the protein and accordingly help find the best virtual 
screening hits [97]. The top hits in this study were 80% superimposed with the results of AutoLigand. This 
could further help in determining the best ligands that could design promising SHALs. 
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CHAPTER 3: MATERIALS AND METHODS 
I. Analysis and homology modeling of HCV proteins 
The sequence of HCV genotype 1b (isolate H) was used to develop homology models for some 
of the HCV proteins and categorize the models that could be created using this sequence according to 
the availability of reliable crystal structures which will affect the accuracy of the obtained model (Table 5). 
The sequence was obtained from UniProtKB/Swiss-Prot P27958; POLG_HCVH (Figure 8).  The 
AS2TS system [90] was used to obtain models for HCV core protein (Figure 8A), E1 glycoprotein (Figure 
8B), NS2-3 protease (Figure 8C), NS3 serine protease (Figure 8D), NS4A (Figure 8E), NS4B (Figure 
8F), NS5A (Figure 8G) and HCV RNA polymerase (NS5B) (Figure 8H). The AS2TS server is available 
online at: http://proteinmodel.org/AS2TS/as2ts.html. 
II. Homology modeling of HCV E2 glycoprotein  
Theoretical models were created using several modelling systems [70, 72, 90] and also using the 
HCV E2 alignment published by Yagnik et al. [34] (Figure 9). The AS2TS system [90] was used to obtain 
an HCV E2 3D model (tertiary structure) based on the alignment model of Yagnik et al. [34] AS2TS was 
also used to create a set of additional draft 3D models based on sequence alignments calculated by 
programs such as Smith–Waterman [99], FASTA [100], BLAST and PSI-BLAST [101]. HCV E2 sequence 
was first threaded through a representative PDB structure library (with a pair-wise sequence identity cut-
off of 70%) using TASSER system [70] to search for the possible folds. The continuous fragments are 
obtained by excision of the threading aligned regions and reassembling them into full-length models. Ab 
initio modeling (Rosetta method [91]) was used to build the missing regions [70]. The full models are then 
created by docking all the obtained domains together. Metropols Monte Carlo simulation was used to do 
the docking of the domains. The aim of the overall process is to obtain the best domain orientation that is 
similar to the full length I-TASSER model but has minimum steric hindrance [70]. The server used is: 
http://zhang.bioinformatics.ku.edu/I-TASSER. The same sequence was submitted to the Phyre server 
http://www.sbg.bio.ic.ac.uk/phyre/ [72].This was followed by viewing the PSI-Blast pseudo-multiple 
sequence alignment to see the results of scanning the sequence against an up-to-date non redundant 
protein sequence library. The number of homologs with low E-values was identified to verify that the used 
alignment is highly reliable. This is followed by alignment interpretation, structure homology detection fold 
recognition, and finally by viewing the “Alignment Accuracy” to determine the predicted accuracy at each 
position of the alignment [72]. After obtaining the five models (Figures 10A-E), one of the CD81-LEL 
binding regions identified by Yagnik et al. [34] was selected and highlighted using AutoDock Tools 1.5.6 
in each model (Figures 11A-E). The aim of this step was to determine the percentage of similarity in this 
binding site in the five models.  
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III. Homology modeling of HCV NS3 serine protease  
The AS2TS system [89] was used to obtain HCV NS3 serine protease models (tertiary structure) 
for the 6 HCV genotypes. The sequences were obtained from pubmed 
(http://www.ncbi.nlm.nih.gov/pubmed/ ) where the accession numbers of the polyproteins of genotypes 1 
to 6 are AAD56196, YP_001469630,  YP_001469631, YP_001469632,  YP_001469633, and 
YP_001469634 respectively. The regions corresponding to NS3 serine protease in genotypes 1 to 6 were 
used to create the models included the amino acid residues : 1056-1204, 1060- 1206, 1062-1210, 1057-
1204, 1057-1205, and 1061 to 1209 (Figures 12A-F). After obtaining the 6 models of NS3 serine 
protease, they were analyzed using the LGA system [92]. LGA calculates the best superposition between 
proteins in addition to identifying the regions of local similarity between the compared models. The 
system is available at: http://proteinmodel.org/AS2TS/LGA/lga.html  [92].   
Another step was done simultaneously with modeling, which is sequence alignment of the 6 
protein sequences used in modeling of NS3 serine protease. ClustalW [102] was used to perform multiple 
sequence alignment of the used protein sequences from the six genotypes. The best match was 
calculated for the selected sequences and they were lined up both as text (Figure 13A) and in graphical 
representation (Figure 13B) to make it easier to see the similarities between the sequences, the 
conserved regions and the differences.  
IV. In silico design of SHALs against CD81-LEL opened (PDB ID: 1G8Q) and 
closed (PDB ID: 1IV5) conformations 
Preparation of CD81-LEL structure and prediction of binding sites  
AutoDock Tools (ADT) 1.5.6 [96, 97,1003] was used to prepare the CD81-LEL crystal structures 
obtained from the Protein Data Bank (PDB) by deleting water molecules, adding polar hydrogens, 
assigning Gasteiger charges, and creating grid bounding boxes with a 1 A spacing for use with 
AutoLigand and a 0.375A spacing for use with AutoDock 4.2. ADT was also used to prepare the positive 
control ligand for the docking experiment by detecting its root and selecting the number of torsions. 
AutoGrid 4.2 [1003] was used to pre-calculate the grids and create the map files that were used by 
AutoLigand to predict the potential binding sites in CD81-LEL. AutoLigand employs a grid-based 
representation of carbon, oxygen, and hydrogen atom centers to identify atomic centers of ligand atoms 
that could bind to atoms on the protein surface and maximize the ligand‟s affinity within the given site. 
AutoLigand can also be used to identify the best binding site on a protein by filling in a contiguous set of 
affinity points using three steps: a) flood fill, b) local migration, and c) ray casting [98]. By varying the 
number of fill points, AutoLigand determines the best total affinity per volume of the fill as the best binding 
site. To identify potential ligand sites, AutoLigand was used to scan the entire CD81-LEL protein using fill 
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sizes from 10 to 210 fill points. The number of grid points in X,Y,Z (grid box) that were used to guide 
AutoLigand was 40, 18 and 38 respectively. The grid centre points of the X,Y, and Z coordinates were 
3.144, 34.966, and 15.812 respectively.  
Virtual screening 
AutoDock 4.2 [96, 97, 1003] was used to perform virtual screening runs using a subset of the 
ZINC small molecule database containing 10,000 molecules taken from the National Cancer Institute-
Diversity Set II (NCI_DSII), Sigma, and Asinex libraries. The parameters were set at 100 for the number 
of genetic algorithm (GA) runs, 150 as the population size, and a maximum number of generations of 
25000. The Lamarckian genetic algorithm in AutoDock was used to perform the docking experiments. 
Docking results were sorted by the lowest binding energy in addition to specific ligand selection criteria 
that would facilitate the design and synthesis of the best SHALs. The virtual screening runs were 
performed using the National Biomedical Computation Resources (NBCR) computer cluster [1004]. Vision 
[85] was used to construct the computational workflows that were used for virtual screening using the 
NBCR cluster. 
Ligand evaluation and in silico design of SHALs 
Several criteria were considered in the selection of the ligands used to design SHALs. During the 
initial examination of the list of ligands predicted to bind to each site by AutoDock, only ligands containing 
one free carboxyl group or one amino group (or one of each) were selected. In the most highly ranked 
cases, these amino or carboxyl groups were not buried in a cavity nor did they interact with the protein 
surface. They were exposed to solvent and were predicted by AutoDock to bind to the protein with the 
functional group pointed in the general direction of the second ligand binding site. Preference was given 
to ligands that were predicted to form multiple contacts with atoms or amino acid residues in or around 
the perimeter of the targeted cavities. Ligands containing two or more free amino or carboxyl groups were 
only considered for use in creating SHALs that might need additional charge to increase their solubility. 
Molecules that were highly hydrophobic, highly charged, known to be toxic, exist in more than one form 
(such as enol-keto forms), or contained disulfide bonds were avoided. After filtering the ligand sets to 
remove the molecules that did not meet these criteria, the predicted binding energy was used to further 
rank the top hits.  A set of ligands predicted to have the lowest binding energy were then used to design 
two prototype SHALs. The distance between the functional groups on pairs of ligands that would be 
linked together was measured and a linker of suitable length was designed using a combination of lysine 
and miniPEG molecules. The linker could be varied by incorporating PEG moieties between the ligands to 
adjust the length of the linker and by inserting lysine residues at key points to enable linker branching 
[17]. 
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V. In silico design of SHALs against HCV NS3 serine protease genotype 4 
This part started by preparing the HCV NS3 serine protease genotype 4 model and prediction of 
binding sites using AutoDock Tools (ADT) 1.5.6 [96, 97,1003]. The number of grid points in X, Y, Z (grid 
box) that used to guide AutoLigand were 78, 44 and 46 respectively. The grid center points of the XYZ 
coordinates were 24.293, 67.762 and 35.552 respectively. AutoDock 4.2 [96, 97,1003] was then used to 
perform virtual screening runs against around 10,000 molecules taken from the National Cancer Institute-
Diversity Set II (NCI_DSII), Sigma, and Asinex libraries. The parameters used were 100 as the number of 
genetic algorithm (GA) runs, 150 as the population size, and a maximum number of generations of 
25000. The Lamarckian genetic algorithm 4.2 was used to do the docking experiments. Docking results 
were sorted by the lowest binding energy in addition to specific ligand selection criteria that would 
facilitate the design and synthesis of the best SHALs. The virtual screening runs were performed using 
the National Biomedical Computation Resources (NBCR) clusters [1004]. Vision [81] was used to 
construct the computational workflows that were used for virtual screening using the NBCR cluster. The 
virtual screening was done against the region involved in NS3-4A complexation (Figures 14). This was 
followed by analyzing the obtained results from virtual screening runs and identifying the virtual screening 
hits that fit into the criteria of selection of ligands suitable for generating SHALs as stated in (III.c).  Where 
molecules that were highly hydrophobic, highly charged, known to be toxic, exist in more than one form 
(such as enol-keto forms), or contained disulfide bonds were avoided. After filtering the ligands and 
obtaining the top hits according to the criteria of selection and lowest energy, the distance between the 
functional groups that would be linked together on the two bound ligands was measured and a linker of 
suitable length was designed using a combination of lysine and miniPEG molecules. Each linker‟s length 
could be varied slightly using the PEG moieties to adjust the length of the linker and using the lysines to 
enable linker branching [17]. 
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CHAPTER 4: RESULTS AND DISCUSSION 
I. General overview of structural modeling and analysis of HCV proteins 
(genotype 1a isolate H) 
Some of the HCV proteins represent a big challenge to model and start targeting to generate anti-
HCV drugs. It is worth trying and exerting effort to obtain reliable models because it is believed that if 
these proteins were targeted they will help generate highly specific anti-HCV drugs. As seen in table 5, 
HCV proteins were categorized by the AS2TS system [90] according to the availability of their crystal 
structures and enough data to generate reliable homology models of these proteins. In general models 
that lie in category A are of good accuracy due to sequence identity with other available structures > 45% 
and coverage of > 75% of the overall sequence. Only two HCV proteins lie in this category, they are 
highlighted in green in table 5, HCV NS3 serine protease (Figure 8D) and HCV RNA polymerase (NS5B) 
(Figure 8H). As for category B models, they are of medium accuracy having sequence identity > 20% and 
coverage of > 75% of the overall sequence, and currently there is no HCV protein that lies in this 
category. Proteins in category C1 are considered of low accuracy, with sequence identity of > 15% and 
coverage of > 50% of the overall sequence. Only HCV NS2-3 protease could help create a C1 model 
(Figure 8C). Category C2 models are usually very low in quality or only small fragments could be created. 
Five C2 models could be obtained based on five HCV proteins which are HCV core protein (Figure 8A), 
E1 glycoprotein (Figure 8B), NS4A (Figure 6E), NS4B (Figure 6F), and NS5A (Figure 8G). As for C3 
models, they are not reliable models due to lack of enough data, in addition to lack of at least one crystal 
or NMR structure. HCV E2 and P7 proteins lie in this category which makes it the hardest challenge of all 
to create models for them.  
II. Homology modeling of HCV E2 glycoprotein  
 
Although creating models of HCV E2 glycoprotein is challenging, several models were created 
(Figures 10A-10E) using different modeling techniques. The sequence alignment used was that of 
Yagnik et al. [34]. This group created a truncated HCV E2 homology model and identified significant 
residues involved in CD81-LEL binding to E2. In addition they identified residues involved in dimerization 
of E1-E2 [34].  AS2TS was one of the modeling methods we used to create the HCV E2 model where the 
structural template was the envelope glycoprotein of the tick-borne encephalitis virus (PDB entry: 1SVB). 
The sequence identity between the E2 and the template was 7.2% which is extremely low (Figure 10A). 
I-TASSER/threading system was another method used to obtain an E2 model which had 6% of sequence 
identity with the crystal structure of protoporphyrinogen IX oxidase (PDB entry: 1SEZ) (Figure 10B). 
Another model created by TASSER had 8% sequence identity with the polyamine oxidase extracted from 
yeast (PDB entry: 1XPQ) (Figure 10C). PSiFR system was used to create a model that had a sequence 
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identity of 15% with E.coli enzyme, quinol-fumarate reductase  (PDB entry: 1KF6) which is still considered 
a low percentage (Figure 10D). The last method used was Phyre method which created a small fragment 
that had a sequence identity of 7% with the structural template PDB 1NB4 (Figure 10E).  
After creating the HCV E2 models, one of the regions identified by Yagnik et al. [34] to be 
significant in CD81-LEL binding to E2 was selected in each model so as to determine the percentage of 
similarity in all five models (Figures 11A-E). It was noticed that the selected region (green region) in the 
five models had some similarity which means it could be the most reliable part to be targeted and to run 
virtual screening against. This step will be carried out later on when obtaining more accurate E2 model.  
III. Homology modeling of NS3 serine protease glycoprotein  
AS2TS was used to create six models of HCV NS3 serine protease corresponding to the 6 HCV 
genotypes. Figures 16A to 16F represent the HCV NS3 serine protease models for genotypes 1 to 6, 
respectively. Several types of comparisons were done for these created models. LGA was used for 
analyzing the models and comparing them to each other on the local basis (specific sequences‟ 
similarities) and globally (throughout the whole alignment.) A dendrogram obtained at the end (Figure 17) 
showed that genotypes 1 (Figure 16A) and 4 (Figure 16D) were the most similar models. It was also 
concluded from observing the dendrogram that genotype 6 is more similar to genotypes 1, 4, followed by 
5 and 3.  Finally, genotype 2 is the least similar to all other genotypes. The same order of similarities was 
confirmed by a purely sequence-based analysis performed using ClustalW (see Figure 13A). Another 
type of comparison was conducted using ClustalW to identify the conserved regions, and how they differ 
among the 6 genotypes. Figure 13B shows that starting from approximately amino acid 80 in the 6 
genotypes the percentage of conserved regions increases leading to the conclusion that this is a good 
region to target so as to obtain a drug that could act on all genotypes. This could be achieved by either 
targeting each NS3 serine protease genotype alone and selecting a region taking amino acid 80 as a 
marker and do virtual screening runs against it or make a model for the whole conserved region as a 
separate pocket, do virtual screening runs against it as a whole and generate SHALs against it which 
might then act as therapeutics against all genotypes.   
IV. In silico design of SHALs against CD81-LEL crystal structures 
Identification of Target Sites on CD81-LEL 
Kitadokoro et al. determined the 3D structure of CD81-LEL using X-ray crystallography [103,104]. 
Two different crystal forms of CD81-LEL (PDB Ids: 1G8Q and 1IV5) were reported [103, 104]. In the 
1G8Q structure the C and D helices form a cleft-like motif within the site of E2 binding which could be 
targeted for inhibitor development. The 1IV5 conformation is considered a closed form of the E2 structure 
 28 
 
in which this cleft is absent. Any ligands binding to the closed conformation would involve interactions 
with 1IV5 in more shallow and surface exposed sites than those observed on 1G8Q [94]. Molecular 
dynamics studies performed by Neugebauer et al. have suggested that the 1IV5 structure may be the 
physiologically relevant conformation. This was attributed to the closure of the cleft in 1G8Q that occurred 
after around 50 ps of molecular dynamic simulations.  The 1G8Q conformation was also considered to be 
less stable because more amino acid residues were found to be outside the favoured energy region of 
Ramachandran plot. In addition, 1IV5 structure had more crystallographic contacts, which would suggest 
that the structure is more stable of the two conformations [94].   
In this study we used both conformations as targets for virtual screening runs to identify ligands 
predicted to bind to the E2 contact residues that were reported previously. Based on mutation studies, 
Higginbottom et al. [52] identified four residues that were considered to be essential for the HCV E2 
protein to bind to CD81-LEL. The D196E mutation in CD81 was observed to reduce binding to E2. In 
addition mutations F186L and E188K inhibited binding of CD81 to E2 where as T163A enhanced their 
fusion (Figure 6A) [52]. Drummer et al. identified an E2 binding site in CD81-LEL of around 806 A°
2
. The 
most important contact residues they found within this site were Ile182, Phe186, Asn184, and Leu162 
(figure 6B) [53]. The identification of these residues provided the information needed to design a series 
of selective high affinity ligands to block the E2-CD81 interaction.  
The AutoLigand fill points and plot analysis 
AutoDock is one of the most widely used docking programs. Recent program modifications and 
the addition of new computational tools that support the program have made the AutoDock even more 
powerful. The AutoDock suite contains two main programs, AutoDock and AutoGrid. AutoDock is used to 
dock the ligand to the region of choice pre-defined by grid maps. The scoring function of AutoDock 
employs a subset of the AMBER force field, implementing the united-atom model [96,97]. AutoGrid, the 
second program, pre-calculates these grids [1003]. AutoDock Tools (ADT) is the graphical user interface 
[96, 97,1003] that helps visualize the grid box and determine the desired site, in addition to analyzing the 
dockings [1003]. AutoLigand, a recently developed AutoDock tool, is used to predict potential binding 
sites in known protein structures. It works by finding the best fill points which have the largest possible 
interaction energy with the protein and using these fill points to identify the best virtual screening hits [98].  
AutoLigand [98] was used to select the best binding sites in CD81-LEL. The protein database 
(pdb) files that are generated represent the fill points that correspond to the different binding sites. 
AutoLigand identified 5 binding sites in 1G8Q and 4 binding sites in 1IV5. The best binding sites were 
determined by plotting the total energy per volume (Kcal/mol A
3
) vs. the volume of the cavity (Figure 18). 
As shown in Figure 18, the plots contain a different number of points having different shapes and colors. 
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In the plot, each group of points having the same shape and colour represent one of the predicted binding 
sites.  
One of the binding sites predicted for 1G8Q (Figure 19A) corresponded to the region that had 
most of the E2 contact residues (Ile182, Phe186, Asn184, Glu188, Asp196) [52]. Another group of fill 
points were found in a neighboring cavity located on the opposite site of the protein (Figure 19B). Both 
regions were predicted to be good binding sites by AutoLigand because they had the largest possible 
interaction energy with CD81-LEL. Consequently, these two sites were selected as the primary sites for 
use in small molecule docking and SHAL development. Figure 20 shows two other regions that were 
predicted by AutoLigand to be good ligand binding sites. These sites were used to identify additional 
small molecules that could be linked to ligands predicted to bind to the first two sites to enable the 
creation of tridentate SHALs (SHALs with three ligands linked together). Tridentate SHALs have been 
shown to exhibit higher affinities for their protein targets than bidentate SHALs containing two ligands 
[100]. The higher the affinity of the inhibitor, the more effective the molecule should be in competing for 
E2 binding.  
AutoLigand identified 4 binding sites on the surface of the closed 1IV5 conformation. One of 
these sites was found to overlap with the region containing the residues that participate in the binding of 
E2 to CD81-LEL. This site and two others (Figure 21) were selected and used in virtual screening runs 
performed with the 1IV5 conformation of CD81. One unexpected observation made during our analysis of 
the fill point energy plot for several of these sites was that sites on the closed conformation might prove to 
be as good as those identified on the open conformation. The predicted binding energies were as low, 
and in some cases lower, than those predicted for the open conformation binding sites.  
Docking and analysis of ligands predicted to bind to the selected sites 
More than twenty new molecular docking programs have been developed since DOCK was first 
introduced by Kuntz in 1982 [34,35]. While these programs use different algorithms to dock two 
molecules together, a variety of methods for handling the flexibility of molecules and the influence of 
water, and one of several scoring functions that evaluate and rank the predicted interactions and the final 
conformations of the molecular components, many of these programs have demonstrated they can 
predict how molecules interact [106, 107]. A number of the more popular programs, such as AutoDock 
[1003], GOLD [108], Flex [109], and DOCK [110] are particularly useful when it comes to predicting how 
small molecules bind to the surfaces of proteins. Run on supercomputers or computer clusters, hundreds 
of thousands of small molecules can be docked to a site on the protein surface using these programs and 
evaluated for their potential to bind to the site in as little as 24 hrs. The AutoDock program suite has many 
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applications, and it is frequently used in fragment based drug design, lead optimization, virtual screening, 
protein-protein docking, and combinatorial library design [1003]. 
Docking runs were performed for three sites located on both the open and closed CD81-LEL 
conformations (1G8Q and 1IV5). The list of ligands predicted to bind to each site were ranked according 
to binding energy and how well the ligand‟s atoms mapped onto the fill points for the site. In addition to 
the fill points defining the rough shape of ligands that would fit best into the cavity, specific fill points are 
also color coded to identify particular atoms (carbon, hydrogen, nitrogen or oxygen) in the ligand that 
would interact optimally with the surface of the protein in the regions surrounding the ligand. An example 
is shown in Figure 22. The fill points predicted for this site by AutoLigand are colored red (for hydrogen 
acceptors such as oxygen or nitrogen), blue for hydrogen atoms, or gray for carbons (Figure 22A). One 
of the better ligands predicted to bind to this site (Figure 22B) have atoms that superimpose well with the 
fill point map (Figure 22C) While the superimposition does not need to match perfectly, the points of 
contact on the protein are considered to be good if the majority of the different atom types in the molecule 
(75-80%) approximate the same location as the fill points. 
The top ranking ligands were further evaluated based on several additional criteria. The most 
important is the requirement that selected ligands contain a single amino or carboxyl group (or one of 
each). Ligands that contain either group can easily be conjugated to a linker (miniPEG or a lysine) using 
the simple peptide-based chemistry used to rapidly synthesize SHALs [18]. The second requirement 
involved the orientation of the bound ligand.  Ligands were only selected if the free carboxyl or amino 
group were predicted by AutoDock to point out toward solvent and in the general direction of the second 
binding site. This would ensure the ligand could still bind to the protein when conjugated to the linker, and 
it would enable both ligands to bind to their respective cavities after being linked together without having 
to adopt an unfavourable conformation. In addition, those ligands that formed multiple 
contacts/interactions with the protein (such as hydrogen bonds, salt bridges, Van Der Waals interactions) 
were considered to be better than those predicted to make only one or two contacts.  
Applying these criteria, a set of ligands was selected for two adjacent target sites on both the 
open and closed conformations of CD81-LEL. Table 6 shows an example of 10 virtual screening hits 
predicted by AutoDock to bind to Site 1 on the open 1G8Q conformation. These molecules are arranged 
in a descending order from good to poor. Ligand 1 was ranked as one of the best candidate ligands 
because it has several atoms that interact with the protein‟s side chains surrounding the cavity through a 
series of hydrogen bonds and Van Der Waals interactions. In addition this ligand has one free amino 
group and one free carboxyl group which enable the ligand to be used to create both bidentate and 
tridentate SHALs. Ligand 3 also appeared to make good contacts with the protein surface, but it was not 
ranked as highly due to the expectation that the ligand, which is more hydrophobic, might contribute to 
 31 
 
the insolubility of any SHALs that contain the molecule. Ligand 7 made good contacts with the protein 
surface, but it didn‟t exhibit the desired selectivity. This ligand was predicted to bind to more than one site 
on the protein. Ligand 10 was considered poor because it is highly hydrophobic. This would not only limit 
its solubility, but it might also direct the molecule to concentrate in adipose tissue. The highly conjugated 
ring structure might also lead to the generation of a metabolic product that could be mutagenic or 
carcinogenic.  
Eight examples of ligands predicted to bind to site 2 and 3 on the open conformation of CD81 
LEL are shown in Table 7. Of those predicted to bind to site 2, ligand 1 is considered to be better 
candidate because the ligand, which is not overly large, makes several contacts inside the binding site in 
addition to having a free carboxyl group. Ligand 2 was ranked as intermediate because it contained two 
amino groups. This would help with SHAL solubility, but it would limit how the ligand could be 
incorporated into a SHAL. Conjugation to the linker could only be performed using the carboxyl group 
(otherwise multiple products would be produced) and the presence of the two free amines would require 
the ligand be incorporated into the SHAL as the last synthesis step. Ligand 3 was ranked as fair because 
it was predicted to have fewer contact points with the binding site. Ligand 4 was ranked as poor, primarily 
because of its small size, minimal contact with the surface, and its lack of specificity. The same ligand 
was also predicted to bind to other sites. The ligands shown for site 3 were ranked in the same manner. 
Similar results were observed for the ligands predicted to bind to the three sites identified on the 
closed conformation of CD81-LEL (PDB ID: 1IV5). Even though this conformation appears to have fewer 
deep cavities that might serve as suitable ligand binding sites, a number of good binding sites were 
identified by AutoLigand. Tables 8 and 9 show twelve examples of ligands that were predicted to bind to 
the three best sites shown in Figure 23. We observed for the ligands predicted to bind to sites on the 
open conformation of CD81-LEL, a similar proportion of ligands were identified that fit well within the 
binding site and made multiple contacts with the surface. Ligand 1 (Table 9, site 3) is an example of one 
of the better ligands.  This ligand was predicted to form three hydrogen bonds with atoms on the surface 
of the protein (Figure 24). Two or three (depending on which ligand functional group, carboxyl or amino, 
is used to attach the ligand to the linker) of these hydrogen bonds would be expected to remain even after 
the ligand is incorporated into a SHAL.  
In addition to identifying ligands that can be used to create a series of small molecule inhibitors 
that block HCV invasion, the molecules predicted to bind to the sites on the two different conformations of 
CD81 LEL can also be used to help determine which CD81 LEL conformation should be targeted for 
therapeutic development. The eighteen molecules shown in Tables 6 and 7 and the twelve molecules 
shown in Tables 8 and 9 will be used in a follow-on experimental study to determine which ligands bind to 
a recombinant form of CD81 LEL. These experiments should not only confirm the presence (or absence) 
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of the open or closed conformations, but it may be possible to use the two ligand sets to obtain 
information on the dynamics of exchange between the two conformational states. 
In silico design of SHALs and controlling the length of linkers for optimum in silico 
binding 
Both bi- and tri-dentate SHALs have been designed using the ligands predicted to bind to 
different sites on the open conformation of CD81 LEL. Functionalized mini-PEGs and protected (FMOC) 
lysine residues were used to link the ligands using a form of chemistry that would generate amide 
linkages. The distance between two ligands was defined by the number of mini-PEG molecules used to 
separate them. Lysines were introduced at specific spots to create branch points. Figure 25 shows an 
example of a bidentate SHAL constructed using two ligands, one predicted to bind to site 1 (ligand 
4)(Figure 25A) and the other predicted to bind to site 2 (ligand 2) (Figure 25B) on the open form of CD81 
LEL. To create this SHAL, the carboxyl group of ligand 2 was conjugated to the alpha amino group of a 
lysine. The amino group of a functionalized mini-PEG was linked to the carboxyl group of the same lysine 
and the amino group of ligand 4 was conjugated to the carboxyl group at the other end of the mini-PEG 
(Figure 25C). Ligands 2 and 4 were selected because they had the desired free carboxyl and amino 
groups respectively.  
Carbodiimide conjugation chemistry could be used to link free amino and carboxyl groups 
together because the chemistry is well established (it has been used for many years for peptide 
synthesis), efficient, inexpensive and fast.  A tridentate SHAL was also designed using a similar approach 
(Figure 26). Both SHALs were designed to demonstrate how the ligands might be combined to create 
candidate inhibitors that bind selectively to CD81. However, before additional effort is put into designing 
other SHALs for synthesis and experimental testing, the sets of ligands predicted to bind to the various 
sites must first be tested experimentally to determine which ligands actually bind to a recombinant form of 
the CD81 LEL protein. The results of the experiments will then be used to identify which combinations of 
ligands should be used to create the SHALs. Confirming ligand binding by experiment is an essential step 
in the process because the docking results are only predictions. Based on our previous docking studies, 
typically 25-65% of the ligands predicted to bind will actually end up binding to the protein.  
V. In silico design of SHALs against HCV NS3 serine protease genotype 4 
model common conserved region 
HCV genotype 4 is the most prevalent in Egypt [111], thus HCV NS3 serine protease genotype 4 
is the target of choice as a start for the in silico design of SHALs. Several important residues in HCV NS3 
serine protease have been identified to form the zinc binding site ( Cys 97, 99, 145 and His 149) [112]. 
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Also there is the active site (trypsin like motif) which constitutes His57, Asp81 and Ser139 [113]. The 
region targeted in this study is the NS3-4A complexation region which mainly includes valine, leucine, 
isoleucine and glycine residues [112]. This region was selected in NS3 serine protease genotype 4 
(Figure 15). Since this region hasn‟t been targeted by others it was important to confirm that this region 
woulad have a good binding site. This was achieved by using AutoLigand to predict all possible binding 
sites on the protein. The results showed that among the potential binding sites predicted there was one 
good site in this region (Figure 27D- Figure 28). This gave us more confidence that this site could be 
targeted and might help generate promising SHALs specifically against genotype 4. After doing virtual 
screening runs against several sites within this region and analyzing the ligands according to the criteria 
of selection, an in silico designed bi-dentate SHAL was created as an example where it included PEG 
and lysine moieties to give length and branching property to the SHAL (Figure 29). After doing the 
experimental studies on the obtained virtual screening hits, synthesizing the SHALs and testing them, the 
success or failure of such an approach could be confirmed. 
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CHAPTER 5: CONCLUSION 
The newly developed AutoDock tool, AutoLigand, enhanced the functionality of AutoDock and 
proved to be helpful in identifying potential ligand binding sites on the surface of CD81-LEL. Two sites on 
the open conformation of CD81 LEL that were selected by AutoLigand were located in regions identified 
by mutational studies to be within the site of E2 binding. These and other sites on both the closed and 
open CD81-LEL conformations were used to perform virtual ligand screening runs using AutoDock. Sets 
of ligands were identified for multiple sites on both conformations of the protein.  Ligands predicted to 
bind to the best sites on the open conformation of CD81 LEL were then used to design a bidentate and 
tridentate SHAL as a demonstration of the process.  
Thirty ligands were also identified for use in a future experimental binding studies aiming at 
determining which conformation of CD81-LEL, open or closed, should be targeted for inhibitor 
development. Eighteen of these ligands were molecules predicted to bind to sites located on the open 
conformation of CD81 LEL. Twelve were molecules predicted to bind to sites located on the closed 
conformation of CD81 LEL. Our next step will be to test both sets of ligands experimentally and use the 
results to 1) provide information about whether or not sites in the open or closed (or both) conformations 
exist long enough for the ligands to bind, 2) provide experimental confirmation that the new AutoDock 
tools enhanced our ability to select the best ligands, and 3) determine which ligand sets should be used 
for SHAL design and synthesis. Different combinations of the molecules that bind to CD81-LEL will then 
be linked together using solid phase chemistry to produce a series of SHALs, and these moleules will be 
tested to confirm that they bind to the target protein CD81 and to determine their affinities for the protein. 
The best SHALs will then be tested in a series of HCV cell culture assays using HCV pseudoparticles 
(HCVpp) to test their ability to inhibit HCV infectivity. Based on the previous work of others, we expect that 
some of these SHALs will not only block the binding of the virus and virus invasion by inhibiting HCV E2-
CD81 interaction [51-54], but may also block the production of cytokines that leads to the induction of liver 
damage [53] and alter the replication of HCV [54]. 
The CASP workshops have shown repeatedly that the most accurate modeling approach is the 
homology modeling method. Thus HCV NS3 serine protease and HCV E2 models were created using 
several modeling systems. The models of NS3 serine protease are considered the most reliable, whereas 
HCV E2 was considered a challenging target because there were no homologs available. Thus only 
models of lower quality could be created. These models need to be optimized when more studies on HCV 
E2 are conducted to identify its complete 3D structure. Modeling is important when there is no specific 
experimentally solved protein structure available but through extensive computational searches possible 
homologs can be identified and used to predict its structure and function.  
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This thesis had several positive outcomes; one is doing an analytical study on the HCV genome 
in relation to the ability to obtain accurate models. Six models of HCV NS3 serine protease of the six HCV 
genotypes were created and multiple sequence alignment was done using ClustalW so as to see the 
similarities and differences between the enzyme in the 6 genotypes. Another promising point is the 
creation of HCV E2 model which when optimized and become reliable enough will be a promising target 
to develop vaccines and powerful anti-HCV drugs.  
Working with different protein targets and predicting sites that might be promising using new 
computational biology tools such as AutoLigand to generate SHALs; might be an effective approach 
targeting different levels of HCV life cycle such as the entry (CD81-LEL), translation (NS3 serine 
protease) and replication (CD81-LEL/NS3 serine protease). This approach could be applied to generate 
diagnostic tests for HCV by acting as carriers and being specific to a certain target, they could also act as 
vaccines by carrying an immunogenic part of HCV E2, but this approach needs more research so as to 
see how to make such a vaccine trigger sustained immunity against HCV.  
This phase focused on doing an analytical study on the HCV genome in relation to the ability to 
obtain accurate models. In addition six models of HCV NS3 serine protease of the six HCV genotypes 
were created and multiple sequence alignment was done using ClustalW so as to see the similarities and 
differences between the enzyme in the 6 genotypes. Another promising point is the creation of HCV E2 
model which when optimized and become reliable enough will be a promising target to develop vaccines 
and powerful anti-HCV drugs.  
Future plans 
The next phase aims at conducting the experimental studies that will include the following (Figure 30): 
1- Binding assays to identify the best ligands that could be used to synthesize SHALs and validate 
computational hits. 
2- Synthesizing SHALs using the solid phase synthesis approach. 
3- Binding assays of SHALs to be sure that after the synthesis the binding affinity increased and 
was specific (negative and positive controls).  
4- Cell culture assays to see if the synthesized SHALs inhibited the infectivity of HCV using HCV pp 
(pseudoparticles) and HCV cc (cell culture).  
5- In vivo studies using the HCV mouse models [115,116].  
By doing the experimental studies, all the computational biology work implemented will 
be verified and will show to be suitable approach in targeting HCV or not. The results of our 
modeling and docking studies suggest that this approach will be effective.  
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CHAPTER 6: LIST OF TABLES AND FIGURES 
Table 1.  Selective NS3/4A serine protease inhibitors [39-45]. 
Drug Clinical trial phase 
Telaprevir Phase III 
Boceprevir Phase III 
TMC435350 Phase II 
ITMN-191 Phase I 
MK-7009 Phase I 
BI201335 Phase II 
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Table 2. HCV proteins reproduced from [4] with permission.  
Protein Molecular mass KDa  Function 
Core 21 RNA binding, nucleocapsid 
E1 31-35 Envelope glycoprotein, associate with E2 
E2 70 Envelope glycoprotein, associate with E2, receptor 
binding 
P7 7 Ion channel 
NS2 21 Component of NS2-3 proteinase 
NS3 69 N-terminal proteinase domain/ C-terminal  
NTPase/Helicase domain 
NS4A 6 NS3/4A proteinase co-factor 
NS4B 27 Induces membrane alterations 
NS5A 56-58 Phosphoprotein 
NS5B 68 RNA dependent RNA polymerase 
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Table 3. Comparison between suitable and non suitable ligands for the generation of SHALs.  
Suitable ligands Non suitable ligands 
Have free amino and/ or carboxyl group Lack an amino or a carboxyl group 
Have 2 amino or 2 carboxyl groups 
The free amino/carboxyl group points 
towards the second site of choice and 
away from the surface 
The free amino/carboxyl group points 
towards the surface and opposite to the 
desired second site of choice 
Hydrophilic molecule  Hydrophobic molecule 
Non toxic compounds Highly toxic compounds 
Commercially available Not available commercially  
Non detergents Detergents  
Compounds with high specificity  Compounds that bind to more than one site 
Modified aminoacids Peptides 
Compounds having functional groups with 
moderate to low reactivity  
Compounds with highly reactive functional 
groups 
Compounds that lack disulfide bonds Compounds that possess disulfide bonds 
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Table 4. Different protein modeling and structure analysis techniques and their characteristics [70,71,90-
93].  
Protein modeling technique Characteristics 
Amino acid Sequence to Tertiary Structure 
(AS2TS) [90] 
Translates the amino acid sequences into 
standard protein databank (PDB) atomic 
coordinates using closely related proteins 
from PDB to produce a set of 3D models 
for the desired target protein. 
Protein Structure and Function prediction 
Resource (PSiFR) [70,71] 
Predicts the structure and function of 
proteins by comparing different protein 
sequences with known and unknown 
functions so as to try to find proteins with 
nearly similar functions 
ROSETTA [91] Predicts protein structures in the presence 
or absence of experimental data of the 
target protein via identifying the relevant 
conformation space when predicting the 
structure of a protein, and sequence space 
in case of protein design. 
Protein Homology/analogY Recognition 
Engine (Phyre) [72] 
Folds recognition-based protein structure 
prediction system by scanning known 
protein structures against a non-redundant 
sequence database obtaining a profile 
which is then saved in the „fold library‟, 
where both the predicted structure and 
experimental structure of this protein are 
stored.  
Local-global alignment (LGA) [92] Compares different protein structures and 
fragments and help classify groups of 
proteins in addition to ranking the level of 
similarity between two structures. 
STRucture ALignment-based Clustering of 
Proteins (STRALCP) [93] 
Determines regions in a given set of 
proteins that possess structural 
similarities. Those regions are then used 
for clustering, yielding protein classification 
schemes based on these structural 
similarities. 
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Table 5. The categorization of HCV proteins according to the accuracy of the structural models that 
could be created using AS2TS system. 
Model Length  Accuracy 
Core protein_P21 191 Category_C2 
Envelope gp_E1 192 Category_C2 
Envelope gp_E2 363 Category_C3 NO 
P7 63 Category_C3 NO 
Protease NS2-3 217 Category_C1 
Serine protease NS3 147 Category_A 
NS4A 54 Category_C2 
NS4B 261 Category_C2 
NS5A 448 Category_C2 
NS5B –RNA polymerase 591 Category_A 
Grouping criteria (E-value <0.02) 
Categories Sequence Id.  Coverage Quality  
Category_A >45 >75 Good 
Category_B >20 >75 Medium 
Category_C1 >15 >50 Low 
Category_C2 Very low homology or small fragments 
Category_C3 No reliable models were created 
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Table 6. Small molecules predicted by AutoDock to bind to Site 1 (main site) on the open conformation 
of CD81-LEL (figure 3). The molecules are listed according to the assessed quality of the ligand and its 
interaction with CD81-LEL in descending order. Atom color codes: hydrogen (light blue), nitrogen (dark 
blue), oxygen (red), sulfur (yellow), and fluorine (green). Criteria used to define the quality of the ligands 
are: Good - makes more than 5 contacts with protein, predicted to be selective and not predicted to bind 
to multiple sites, not too hydrophobic; Intermediate - makes 4-5 contacts with protein, hydrophobic 
interactions contribute to binding; Fair – makes 3-4 contacts with protein; Poor – makes less than 3 
contacts with protein, large conjugated ring structures, molecule is hydrophobic and does not fit well 
inside the cavity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3       Hydrogen 
      Oxygen 
       Nitrogen  
       Sulfur 
       Fluoride 
Good: 
 >5 interacting contact points 
 Predicted to be selective based on 
interaction, hydrophobicity and size. 
Intermediate: 
 4-5 interacting contact points 
 Predicted to be of less selectivity due to 
higher hydrphobicity 
Fair: 
 3-4 interacting contact points 
Poor:  
 <3 interacting contact points 
 Has large number of rings that doesn’t fit 
well into the binding site, thus not 
selective.  
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Table 7. Small molecules predicted by AutoDock to bind to Site 2 and Site 3 on the open conformation of 
CD81-LEL (figure 3). The molecules are listed according to the assessed quality of the ligand and its 
interaction with CD81-LEL in descending order. Atom color codes: hydrogen (light blue), nitrogen (dark 
blue), oxygen (red), sulfur (yellow), and fluorine (green). Criteria used to define the quality of the ligands 
are: Good - makes more than 5 contacts with protein, predicted to be selective and not predicted to bind 
to multiple sites, not too hydrophobic; Intermediate - makes 4-5 contacts with protein, hydrophobic 
interactions contribute to binding; Fair – makes 3-4 contacts with protein; Poor – makes less than 3 
contacts with protein, large conjugated ring structures, molecule is hydrophobic and does not fit well 
inside the cavity. 
 
# Ligand Potential quality 
Site 2 
1  
 
 
Good  
2  
 
 
Intermediate  
3  
 
 
Fair  
4  
 
 
Poor  
Site 3 
1  
 
 
Good  
2  
 
Intermediate  
3  
 
Fair  
4  
 
Poor  
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Table 8: Small molecules predicted by AutoDock to bind Site 1 on the closed conformation of CD81-LEL. 
The molecules are listed according to the assessed quality of the ligand and its interaction with CD81-LEL 
in descending order. Atom color codes: hydrogen (light blue), nitrogen (dark blue), oxygen (red), sulfur 
(yellow), and fluorine (green). Criteria used to define the quality of the ligands are: Good - makes more 
than 5 contacts with protein, predicted to be selective and not predicted to bind to multiple sites, not too 
hydrophobic; Intermediate - makes 4-5 contacts with protein, hydrophobic interactions contribute to 
binding; Fair – makes 3-4 contacts with protein; Poor – makes less than 3 contacts with protein, large 
conjugated ring structures, molecule is hydrophobic and does not fit well inside the cavity. 
Ligand Structure Potential quality 
  Site 1 
  
 
 
 
Good  
2  
 
 
 
Intermediate  
3  
 
 
 
Fair  
4  
 
 
 
Poor  
 
 
 
 
 
 
3 
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Table 9. Small molecules predicted by AutoDock to bind Site 2 and Site 3 on the closed conformation of 
CD81-LEL. The molecules are listed according to the assessed quality of the ligand and its interaction 
with CD81-LEL in descending order. Atom color codes: hydrogen (light blue), nitrogen (dark blue), oxygen 
(red), sulfur (yellow), and fluorine (green). Criteria used to define the quality of the ligands are: Good - 
makes more than 5 contacts with protein, predicted to be selective and not predicted to bind to multiple 
sites, not too hydrophobic; Intermediate - makes 4-5 contacts with protein, hydrophobic interactions 
contribute to binding; Fair – makes 3-4 contacts with protein; Poor – makes less than 3 contacts with 
protein, large conjugated ring structures, molecule is hydrophobic and does not fit well inside the cavity. 
 
Ligand Structure Potential quality 
Site 2 
1  
 
 
Good  
2  
 
Intermediate  
3  
 
Fair  
4  
 
 
Poor  
Site 3 
1  
 
 
Good  
2  
 
Intermediate  
3  
 
 
Fair  
4  
 
 
Poor  
 
3 
3 
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Figure 1. E2 homology model . Reproduced from [34].  
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Figure 2. The difference between the envelope glycoproteins of HCV and TBEV. (A) The components of 
the outer shell of both TBEV and HCV where E1-E2 tetramer forms the outer shell incase of HCV and E-
protein dimer forms the outer shell incase of TBEV. (B) The proposed outer shell structure of HCV formed 
of E1-E2 tetramers. Reproduced from [35].  
 
 
 
 
 
 
 
 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
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Figure 3. The predicted (A) monomeric and(B) dimeric models of HCV E2. (C & D) The nine mimotopic 
fragments that were chosen by Spiga et al. Reproduced from [36]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
(D) 
(C) 
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Figure 4. HCV genome . Reproduced from[116]. 
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Figure 5. Proposed models for HCV entry into the host cells. (A) LDL-R and Glycosaminoglycan plays the 
initial role by mediating the attachment of HCV associated with liporptoeins to CD81 and SRBI which 
upon interacting will trigger HCV movement to the tight junction proteins (Such as claudin-1 (CLDN1)) 
followed by clathrin mediated endocytosis. (B) A proposed model that differsfrom model (A) in having an 
extra tight junction protein (OCLDN) involved in the HCV entry by acting as the final key in HCV entry 
process. (A) and (B) are reproduced from [85] and [30] respectively.                                                                                                                                          
 
 
                            
                         
                              
 
 
 
 
 
                                                                                                                                                   (B) 
 
 
 
 
 
 
(A) 
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Figure 6: CD81-LEL open conformation (PDB ID: 1G8Q). The colored residues are amino acids that have 
been identified to contribute to the binding of the HCV protein E2 to CD81-LEL. (A) Front view of the 
protein showing the four contact residues Leu162, Ile182, Asn184, and Phe186. (B) Back side of the 
CD81-LEL protein showing the other three contact residues Thr163, Glu188 and Asp196 [52, 53]. Figure 
prepared using AutoDock Tools version 1.5.6.  
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Figure 7: Components of selective high affinity ligands (SHALs) 
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Figure 8: The complete genome of HCV genotype 1a isolate H (complete genome (UniProtKB/Swiss-Prot 
P27958; POLG_HCVH): 3011 aa). 
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Figure 9: FASTA format of the protein sequence of some HCV proteins, their modeling trials, and their 
sequence identity percentage with known PDB  structures. 
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Figure 10: The HCV E2 glycoprotein sequence alignment used in obtaining the E2 homology models and 
obtained from [34].  
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Figure 11: Theoretical model of the Envelope Glycoprotein E2 created by AS2TS system (A), I-TASSER 
threading/ab-initio system (B, C), PSiFR threading system (D), and PHYRE fold recognition system (D).  
 
(A) 
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 59 
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(E) 
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Figure 12: Comparing one of the identified CD81-LEL binding sites on HCV E2 by Yagnik et al. in the 4 
models; AS2TS model (A), TASSER models (B, C), PSiFR model (D), and Phyre model (E) to see if the 
binding pocket have certain percentage of similarity.  
 
(A) 
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 66 
 
Figure 13: HCV NS3 serine protease sequences for the six HCV genotypes. NS3 serine protease 
sequences of genotypes 1 (A), 2 (B), 3 (C), 4 (D), 5 (E) and 6 (F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
 
Figure 14: HCV NS3 serine protease sequence alignment of the 6 genotypes so as to determine the 
conserved regions (A), and a graphical representation (B) [102]. 
 
 
(A) 
 
 
(B) 
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Figure 15: Vision interface showing an example of the virtual screening workflow [85]. 
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Figure 16: Significant residues in NS3-4A genotype 4 complexation selected using AutoDock Tools 1.5.6 
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Figure 17: The created NS3 serine protease models of the six HCV genotypes; GT 1 (A), GT 2 (B), GT 3 
(C), GT 4 (D), GT 5 (E), and GT 6 (F). 
(A) 
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(B) 
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(D) 
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(E) 
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(F) 
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Figure 18: The dendrogram representing sequence similarity-based clustering of 6 genotypes of HCV 
serine proteases NS3. For each genotype of NS3 serine protease a structural model was created by 
AS2TS system, and sequence similarities were calculated from structural alignments using Local – Global 
Alignment (LGA) analysis. 
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Figure 19: Predicted free energy data for ligand binding sites identified on the surface of CD81-LEL by 
AutoLigand. Data for fill points within a given site are shown as a set of colored squares or circles. (A) 
CD81-LEL open conformation (PDB ID: 1G8Q). (B) CD81-LEL closed conformation (PDB ID: 1IV5). 
Figure prepared using AutoDock Tools version 1.5.6. 
 
(A) 
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(B) 
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Figure 20: Two ligand binding sites identified by AutoLigand on the open conformation of CD81-LEL 
(PDB ID: 1G8Q). These two sites were selected as docking targets based on their proximity to the amino 
acid residues that contact E2 (colored in yellow) and the low free energy (high affinity) predicted for 
ligands that would bind in this site. (A) The green spheres define the ligand binding site predicted by 
Autoligand to be the best binding site. Ligands binding to this site would interact directly with several key 
amino acids in the E2 binding site. The green spheres correspond to the green circle fill points in figure 
16A located between 500 and 600 A
3
. (B) The black spheres identify a second binding site predicted by 
AutoLigand on the opposite side of the protein. Ligands binding to this site should also contribute to the 
disruption of E2 binding. The black spheres correspond to the black square fill points shown in figure 16A 
located between 550 and 650 A
3
. Figure prepared using AutoDock Tools version 1.5.6 
(A) 
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(B) 
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Figure 21: Two additional binding sites (shown filled with green spheres) predicted by 
AutoLigand on the open conformation of CD81-LEL (PDB ID: 1G8Q). The amino acids that 
contact E2 are colored yellow. These binding sites correspond to the fill points shown as green 
circles in Figure 16A that are located between 200 and 300 A3. (A) The green fill points identify 
Site 4. (B) The green fill points identify Site 3. Figure prepared using AutoDock Tools version 
1.5.6. Figure prepared using AutoDock Tools version 1.5.6. 
 
 
 
 
 
 
 (A) 
 
 
 
 
 
 
 
 
 
 (B) 
 
 82 
 
Figure 22: Ligand binding sites predicted by AutoLigand on the surface of the closed conformation of 
CD81-LEL (PDB ID: 1IV5). Site 1 (the cluster of blue fill points) was located between 500 and 700 A
3
 in 
Figure 3B, and Site 2 (the smaller cluster of green fill points located to the left of the large blue cluster) 
was located between 500 and 600 A
3
 in Figure 3B. Site 3 is marked by a small group of green fill points 
just barely visible on the far left side of the protein. The yellow residues are the amino acids that have 
been shown to contribute to E2 binding. Figure prepared using AutoDock Tools version 1.5.6. 
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Figure 23: AutoLigand fill points not only identify cavities on the surfaces of proteins, but they also predict 
the structural features of ligands that would bind with the best affinity and selectivity to the protein at 
these sites. (A) The fill points provided by AutoLigand define the rough shape of ligands that would fit best 
into the cavity. Specific fill points are also color coded (gray, carbon; light blue, hydrogen; and red, 
hydrogen acceptors oxygen and nitrogen) to identify particular atoms in the ligand that would interact 
optimally with the protein‟s atoms or functional groups in the regions surrounding the ligand. (B) Ligand 1 
(table 6)  is shown bound to CD81-LEL in the location and orientation predicted by AutoDock.  (C) The 
superposition of fill points and atom types in Ligand 1 is high (75-80%) indicating that this ligand should 
bind well in this particular site. Figure prepared using AutoDock Tools version 1.5.6. 
 
(A) 
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Figure 24. Ligand 1 (table 9) is shown binding to Site 2 in the closed conformation of CD81-LEL (PDB ID: 
1IV5). The three hydrogen bonds that contribute to the stability of the predicted interaction between the 
ligand and protein are shown as gray spheres. Figure prepared using AutoDock Tools version 1.5.6 
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Figure 25: An example of a bidentate SHAL designed using two ligands predicted to bind to Site 1 and 
Site 2 on the open conformation of CD81-LEL. (A) Location and orientation of ligand 2 (table 7) binding 
predicted by AutoDock. (B) Location and orientation of ligand 4 (table 6) binding predicted by AutoDock. 
(C) Structure of the bidentate SHAL. The linker was created using a single miniPEG and lysine and the 
resulting spacing between ligands was sufficient to allow the individual ligands to bind to the predicted 
sites. 
(A) 
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(C) 
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Figure 26. An example of a tridentate SHAL designed to bind to three sites on the open conformation of 
CD81-LEL. This SHAL was designed using three ligands in which one ligand (Ligand 2) has both a free 
amino and a free carboxyl group. 
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Figure 27: Predicted binding sites using plot_set_results for HCV NS3 protease genotype 1 (A), 2 (B), 3 
(C), 4 (D), 5 (E), and 6 (F).  
(A) 
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(B) 
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(D) 
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(E) 
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(F) 
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Figure 28: NS3 residues involved in complexation of NS3-4A together with one of the autoligand 
predicted sites in genotype 4 represented by the blue balls that correspond to the blue circles in the plot 
figure 23-D that are in the volume range of 400 to 600 A
3
. 
 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 98 
 
Figure 29: An example of an in silico designed SHAL against NS3 serine protease genotype 4 model. 
The distance between the amino group of one ligand and the carboxyl group of the other was around 20 
A (A). The SHAL was designed according to the distance between the 2 ligands and their orientation (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
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Figure 30. The flowchart of the overall process of generating SHALs against different HCV targets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Determining the protein 
targets (HCV/host)
Prepare target proteins
Do virtual screening runs 
using different fragment 
libararies
Analyze the results and 
determine the top hits
Initial binding assays to 
obtain the fragments 
that binds to the target 
protein in vitro using 
BIACore or NMR
Fragment optimization 
according to 
computational biology 
studies of the binding 
site 
Synthesis of SHALs using 
Fmoc method. 
Binding assays to ensure 
that SHALs bind to the 
targeted sites with 
reasonable affinity 
Generation of drug leads 
Testing in vivo 
SHALs design in silico 
based on the distance 
between the binding 
sites of 2 or 3. 
fragments. 
Testing these SHALs in 
vivo 
Binding assays to 
ensure the optimized 
ligands bind to the 
targeted sites with 
reasonable affinity 
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